GSK Commit Lozenge Phase IV Studies On Contraindications, AEs Planned
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline's Phase IV obligations for its Commit nicotine polacrilex lozenge include a study of consumers who are contraindicated for use of the OTC smoking cessation drug due to underlying health conditions, FDA's Oct. 31 approval letter states
You may also be interested in...
Rapid Release, Rapid Success: Tylenol Launch Spawns Generic Imitators
The recent success of Tylenol Extra Strength Rapid Release Gels has caught the attention of private labelers
GSK Respiratory OTC Sales Up 13% In Q1
Sales for GlaxoSmithKline's OTC respiratory tract products, which include the Contac cold and flu remedy, rose 13% to $57.7 mil. (£1=$1.60) during the first quarter, the firm announced April 30. Contac primarily is marketed in the U.S., UK, Mexico, China and Japan
Commit Sales Contribute To 25% Gain In GSK Smoking Cessation Sales In Q4
Sales of GlaxoSmithKline's Commit nicotine polacrilex lozenge helped drive the company's fourth quarter smoking cessation sales to $198 mil., up 25% at constant exchange rates compared with the year-ago period